Morphosys Ag Stock Price, News & Analysis

MorphoSys has appointed Sung Lee as Chief Financial Officer, effective February 2, 2021. He takes over from Jens Holstein, who resigned in December 2020. Lee, bringing over 20 years of financial leadership experience, previously served as CFO at Sangamo Therapeutics and held key roles at Gilead Sciences. His appointment is timely as MorphoSys aims to enhance its presence in hematology-oncology and autoimmune diseases. The management believes Lee's expertise will support its ambitious growth strategy and help advance its clinical pipeline.

MorphoSys AG announced its corporate calendar for 2021, detailing key financial reporting dates. The year-end results for 2020 will be published on March 15, 2021, followed by a conference call on March 16, 2021. Additional reports will be released on May 5, July 28, and November 10 for interim statements throughout the year. Furthermore, the Annual General Meeting is scheduled for May 19, 2021. MorphoSys focuses on developing innovative therapies, particularly for cancer, and has several products in clinical development.

MorphoSys AG has announced its 2021 financial reporting dates, including the Year-End Results on March 15, 2021 and the first quarter results on May 5, 2021. The Half-Year Report is scheduled for July 28, 2021, while the Third Quarter Statement will be released on November 10, 2021. The Annual General Meeting will be held on May 19, 2021. Investors can access the full calendar on the corporate website. MorphoSys focuses on developing innovative therapies for serious diseases, notably cancer, and has a significant pipeline including Monjuvi and Tremfya.

On December 7, 2020, MorphoSys AG and Incyte presented preliminary safety and efficacy data from their Phase 1b firstMIND trial at the 62nd ASH Annual Meeting. This study evaluated the combination of tafasitamab and lenalidomide alongside R-CHOP for newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL). Results showed a 91.1% objective response rate among 45 patients. Serious adverse events were noted, but overall tolerability was deemed acceptable. The partners plan to initiate the Phase 3 frontMIND trial in 2021, further exploring tafasitamab's therapeutic potential.

MorphoSys AG (FSE:MOR) announced that its licensee, Janssen Research & Development, received European Commission approval for Tremfya (guselkumab) to treat adult patients with active psoriatic arthritis (PsA) who failed prior DMARD therapy. Tremfya is the first human monoclonal antibody targeting IL-23, previously approved for plaque psoriasis. The approval was based on the successful DISCOVER-1 and DISCOVER-2 Phase 3 trials, which showed Tremfya was well-tolerated in 1,120 patients. This new treatment offers options for PsA patients in Europe, where up to one-third of psoriasis patients may develop PsA.

MorphoSys has appointed Thomas Biegi as Vice President and Head of Corporate Communications, effective December 1, 2020. Biegi joins from Pfizer, where he led global communications for its oncology division. His role is pivotal following the successful launch of Monjuvi in the U.S., as he aims to enhance the company’s positioning in oncology and autoimmune diseases. MorphoSys focuses on innovative therapies, notably the monoclonal antibody Monjuvi, which is under regulatory review in the EU for treating relapsed or refractory lymphoma.

MorphoSys AG (FSE:MOR) reported significant growth in its financial results for the first nine months of 2020, achieving group revenue of €291.7 million, a remarkable increase from €60.7 million in 2019. The company’s new product, Monjuvi(R) (tafasitamab-cxix), generated Q3 sales of $5.0 million. EBIT improved to €101.8 million, up from a loss of €56.3 million in 2019. Liquidity stood at €987.2 million, with updated guidance for 2020 projecting revenues of €317 to €327 million. Additionally, MorphoSys announced strategic partnerships to enhance its R&D efforts in cancer treatment.

MorphoSys AG and Cherry Biolabs GmbH have entered into an exclusive licensing agreement allowing MorphoSys to use Cherry's Hemibody technology to target six exclusive cancer targets. This partnership aims to develop advanced T-cell engaging therapies with improved precision and safety profiles for cancer treatment. The collaboration leverages MorphoSys’ expertise in antibody development alongside Cherry's innovative technology. The financial details of the agreement remain undisclosed, but this move is seen as a significant step towards enhancing cancer treatment options.

MorphoSys AG (FSE:MOR; NASDAQ:MOR), in collaboration with Xencor and Incyte, is investigating a new combination therapy using tafasiatamab, plamotamab, and lenalidomide for treating diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). The Phase 1/2 study will assess its effectiveness in patients with relapsed or refractory conditions in North America, Europe, and Asia-Pacific. Tafasitamab is already FDA-approved in combination with lenalidomide for a specific DLBCL indication. The collaboration aims to enhance treatment options for patients with unmet medical needs.